Denali Therapeutics Inc. financial data

Symbol
DNLI on Nasdaq
Location
South San Francisco, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 949% % -20%
Debt-to-equity 13% % 36%
Return On Equity -46% % -41%
Return On Assets -41% % -36%
Operating Margin -66% % 83%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 146,661,833 shares 1.9%
Common Stock, Shares, Outstanding 146,625,722 shares 1.9%
Entity Public Float $1,900,000,000 USD -5%
Weighted Average Number of Shares Outstanding, Basic 172,421,492 shares 1.7%
Weighted Average Number of Shares Outstanding, Diluted 172,421,492 shares 1.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $295,390,000 USD 191%
Revenue from Contract with Customer, Excluding Assessed Tax $0 USD -100%
Research and Development Expense $420,660,000 USD 4%
General and Administrative Expense $127,163,000 USD 27%
Operating Income (Loss) $547,823,000 USD -12%
Net Income (Loss) Attributable to Parent $498,744,000 USD -17%
Earnings Per Share, Basic -2 USD/shares -4.7%
Earnings Per Share, Diluted -2 USD/shares -6.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $90,963,000 USD 0.36%
Marketable Securities, Current $757,241,000 USD 1.5%
Assets, Current $882,598,000 USD 1.6%
Property, Plant and Equipment, Net $53,732,000 USD 5.7%
Operating Lease, Right-of-Use Asset $20,035,000 USD -16%
Other Assets, Noncurrent $25,106,000 USD -5.2%
Assets $1,055,621,000 USD -27%
Accounts Payable, Current $6,745,000 USD -30%
Employee-related Liabilities, Current $18,358,000 USD 23%
Accrued Liabilities, Current $4,942,000 USD 2.3%
Liabilities, Current $90,146,000 USD 3.5%
Operating Lease, Liability, Noncurrent $29,686,000 USD -24%
Liabilities $129,424,000 USD -4.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax $1,101,000 USD -80%
Retained Earnings (Accumulated Deficit) $1,922,975,000 USD -35%
Stockholders' Equity Attributable to Parent $926,197,000 USD -30%
Liabilities and Equity $1,055,621,000 USD -27%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $131,468,000 USD -16%
Net Cash Provided by (Used in) Financing Activities $3,762,000 USD -101%
Net Cash Provided by (Used in) Investing Activities $18,748,000 USD
Common Stock, Shares Authorized 400,000,000 shares 0%
Common Stock, Shares, Issued 146,625,722 shares 1.9%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $116,482,000 USD -75%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $94,069,000 USD 2%
Deferred Tax Assets, Valuation Allowance $487,714,000 USD 30%
Deferred Tax Assets, Gross $504,057,000 USD 30%
Operating Lease, Liability $38,850,000 USD -17%
Payments to Acquire Property, Plant, and Equipment $5,078,000 USD 136%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $503,172,000 USD -19%
Lessee, Operating Lease, Liability, to be Paid $45,128,000 USD -21%
Property, Plant and Equipment, Gross $107,278,000 USD 17%
Operating Lease, Liability, Current $9,164,000 USD 14%
Lessee, Operating Lease, Liability, to be Paid, Year Two $12,584,000 USD 3.3%
Lessee, Operating Lease, Liability, to be Paid, Year One $12,182,000 USD 3.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $6,278,000 USD -37%
Lessee, Operating Lease, Liability, to be Paid, Year Three $13,001,000 USD 3.3%
Deferred Tax Assets, Operating Loss Carryforwards $113,397,000 USD 27%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 40,000,000 shares 0%
Unrecognized Tax Benefits $33,761,000 USD 29%
Lessee, Operating Lease, Liability, to be Paid, Year Four $4,381,000 USD -66%
Operating Lease, Payments $11,698,000 USD 3.3%
Additional Paid in Capital $2,846,278,000 USD 4.1%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $2,325,000 USD 7.5%
Deferred Tax Assets, Net of Valuation Allowance $16,343,000 USD 36%
Share-based Payment Arrangement, Expense $100,760,000 USD -2.9%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%